Human botulinum neurotoxin A/B immune globulin is human-derived IgG antibodies against botulism toxin types A and B used in the treatment of infant botulism. Infant botulism is a rare infectious disease occurring in infants in which Clostridium botulinum colonize the large intestine and being to produce botulinum neurotoxin directly in the gut.
- Mechanism
- Curator reviewed · 3 references
Infant botulism is a rare infectious form of botulism in which spores of Clostridium botulinum colonize the large intestine. In contrast to foodborne botulism, in which botulinum toxin is ingested by eating contaminated food, patients with infant botulism produce botulinum toxin directly in the large intestine owing to its colonization by C. botulinum.
Human-derived botulism immunoglobulin, also called BabyBIG, comprises purified human immunoglobulin G directed against botulinum neurotoxins A and B. It is derived from pooled adult plasma from persons immunized with recombinant botulinum vaccine, who were then selected for their high titers of neutralizing antibodies against botulinum toxins A and B. These neutralizing antibodies, when administered to the patient, serve to bind to and neutralize circulating botulinum toxin.
- Primary indication
- Human-derived botulism immune globulin is indicated for the treatment of infant botulism caused by toxin types A or B in patients ≤1 year of age.Curator reviewed · 1 structured indication
- First approval
- United States, 2003
- Also known as
- BabyBIG · Botulism immune globulin intravenous (human) · Botulism immune globulin intravenous (human) (BIG-IV) · Botulism immune globulin IV human · Human-derived botulism antitoxin antibodies
- Brand names
Resolves to
What you can answer from here — as of April 02, 2025
Which other approved drugs treat the same conditions as Human botulinum neurotoxin A/B immune globulin, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account